Jim Cramer's Assessment of D-Wave Quantum: A Promising Yet Speculative Venture
Money

Jim Cramer's Assessment of D-Wave Quantum: A Promising Yet Speculative Venture

authorBy Vicki Robin
DateApr 12, 2026
Read Time2 min

Jim Cramer, a prominent financial analyst, has cast a spotlight on D-Wave Quantum Inc. (QBTS), a company at the forefront of quantum computing. He described D-Wave as a 'science project,' acknowledging both its experimental nature and its inherent potential. This assessment came during a discussion about the tech market's volatile speculative segment, particularly in response to a caller's query about D-Wave's rebound prospects.

Highlighting the inherent risks and rewards in this cutting-edge sector, Cramer elaborated on D-Wave's recent stock performance, noting its significant fluctuations. After a climb from $18 to almost $47 by mid-October, the stock experienced a nearly 40% decline, settling below $30. He pointed out that while the company's third-quarter earnings exceeded forecasts, its revenue of $3.7 million underscores the nascent stage of quantum computing technology. Despite these challenges, D-Wave's stock showed a brief rally post-earnings, though it concluded the week with a notable dip, mirroring the broader struggles within the speculative tech market.

D-Wave Quantum Inc. is dedicated to developing advanced quantum computing systems, offering solutions such as Advantage quantum computers, Ocean developer tools, and Leap cloud and hybrid solver services. The company's journey reflects the dynamic and often unpredictable nature of investing in groundbreaking technological advancements. For investors intrigued by the future of computing, D-Wave represents a venture into a field ripe with innovation, where long-term vision may yield substantial returns, albeit with the understanding of its current developmental phase.

More Articles
Money
Jim Cramer's Skepticism on Newsmax (NMAX) Amidst Financial Challenges
Renowned financial commentator Jim Cramer has expressed a pessimistic outlook on Newsmax (NMAX), citing the company's financial losses. He categorizes NMAX as a 'meme stock,' indicating its value is heavily influenced by social media trends rather than traditional market fundamentals. Cramer advises caution against investing in companies currently experiencing financial deficits, suggesting that such ventures often lead to unfavorable outcomes for investors.
By Mr. Money MustacheApr 12, 2026
Money
BofA Adjusts Pfizer's Price Target Amidst Legal and Clinical Developments
Bank of America has revised its price target for Pfizer (PFE) from $27 to $26, maintaining a Neutral rating. This adjustment follows a review of large-cap pharmaceutical and biopharmaceutical coverage. Recent events include a Belgian court order for Poland and Romania to purchase €1.9 billion in COVID-19 vaccines from Pfizer and promising Phase 3 trial results for its Lyme disease vaccine candidate.
By Chika UwazieApr 12, 2026
Money
Allogene Therapeutics: Analysts Predict Over 180% Growth Potential
Analysts are highly optimistic about Allogene Therapeutics (ALLO), with a significant majority issuing 'Buy' ratings. A consensus price target of $7.50 suggests an impressive upside of over 186%. This positive sentiment follows promising developments in their ALPHA3 study and a strong financial position, extending their operational runway into 2028.
By Natalie PaceApr 12, 2026
Money
Mario Gabelli's Insight: American Express's Enduring Appeal in Payment Landscape
Mario Gabelli's investment firm, GAMCO Investors, has maintained a significant interest in American Express (AXP) for many years. Despite trimming its holdings over time, the payments giant remains a favorite due to its affluent customer base and unique dual role as both a card issuer and payment network. AXP's profitability is driven by transaction volume, capturing a percentage of every dollar spent on its cards, especially with strong growth from Gen-Z and Millennial customers.
By Natalie PaceApr 12, 2026
Money
Devon Energy (DVN) Recognized as a Top Value Large-Cap Stock
Devon Energy (DVN) is highlighted as a leading affordable large-cap stock. Recent analyst upgrades from BMO Capital and Morgan Stanley, driven by geopolitical oil market sensitivity and strong energy prices, have boosted its price targets. Truist also initiated coverage with a 'Buy' rating, citing potential from the Coterra transaction. The company primarily focuses on oil, natural gas, and natural gas liquids exploration and production in the United States, positioning it favorably in the current energy landscape.
By Vicki RobinApr 12, 2026